Mutant Prourokinase with C1-Inhibitor is a Safer Alternative to tPA in Rat Stroke Treatment
Author Information
Author(s): Simone Tomasi, Paolo Sarmientos, Giada Giorda, Victor Gurewich, Alessandro Vercelli, Christoph Kleinschnitz
Primary Institution: Neuroscience Institute Cavalieri Ottolenghi (NICO), San Luigi Gonzaga Hospital, Turin, Italy
Hypothesis
Can adjunctive C1-inhibitor improve the safety and efficacy of mutant prourokinase in treating stroke in rats?
Conclusion
The study found that adjunctive C1-inhibitor significantly reduced bleeding complications associated with mutant prourokinase without compromising its thrombolytic efficacy.
Supporting Evidence
- Fatal intracranial hemorrhage occurred in 57% of tPA and 75% of M5 rats without C1-inhibitor.
- Adjunctive C1-inhibitor reduced fatal hemorrhage to 25% for tPA and 17% for M5.
- Both M5 and tPA showed similar ischemic volume reductions, indicating comparable efficacy.
Takeaway
Researchers tested a new treatment for stroke in rats that combines a modified drug with a helper protein, which made it safer and just as effective as the standard treatment.
Methodology
The study used two rat stroke models to compare the effects of tPA, mutant prourokinase (M5), and M5 with C1-inhibitor on intracranial hemorrhage and ischemic volume.
Potential Biases
Potential bias in the selection of treatment groups and the small sample size for some groups.
Limitations
The study was conducted on rats, which may not fully represent human responses to the treatments.
Participant Demographics
Male adult Sprague-Dawley rats weighing 270–350 g.
Statistical Information
P-Value
p=0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website